S&P/ASX 200 Index (ASX: XJO) shares rose 2.77% and delivered total returns, including dividends, of 7% in FY26.
Here, we review three fresh buy, hold, and sell calls from expert market analysts.
Image source: Getty Images
Weebit Nano Ltd (ASX: WBT)
The Weebit Nano share price soared 414% in FY26 to finish at $8.35 per share.
This was a vastly different performance to many of its peers, which suffered major declines amid a broader tech sector rout.
Weebit develops advanced semiconductor memory technology.
Mark Elzayed from Investor Pulse reckons there's more growth ahead for this ASX tech share.
He explains his buy rating on The Bull this week:
Licensing deals with Texas Instruments and onsemi have contributed to company performance. Revenue guidance of $10 million in full year 2026 and a recent capital raising of $102 million fortifies the balance sheet for artificial intelligence and research development.
The shift towards a recurring royalty model generates long term operating leverage.
Momentum and news flow are positive, although the multi year path from licence to royalty income remains the key execution risk.
Metals X Ltd (ASX: MLX)
The Metals X share price ripped 142% to close out FY26 at $1.32.
Elzayed has a hold rating on this ASX materials share.
He explained:
The company is Australia's largest tin producer. It has a 50 per cent equity interest in the Renison tin operation in Tasmania.
Revenue of $285 million in full year 2025 was up 30 per cent on the prior corresponding period.
However, much of this tin market tightness and consolidation now appears priced into the stock.
The stock is already reflecting a bullish structural tin thesis.
So, in our view, MLX is better suited to holding than buying at these levels.
Pro Medicus Ltd (ASX: PME)
The Pro Medicus share price fell 29% in FY26 amid a savage healthcare sector downturn.
However, the stock price of this medical imaging software provider has been recovering strongly since hitting a 52-week low of $107.75 in February.
Pro Medicus shares are up by more than 70% since hitting that floor.
The broader healthcare sector pivoted on 3 June and is also rapidly rising.
Tony Locantro from Alto Capital has a sell recommendation on this ASX 200 healthcare share.
Locantro explained:
The company recently delivered an outstanding first half result in full year 2026. Underlying earnings before interest and tax was up 29.7 per cent and revenue was up 28.4 per cent amid securing more than $A280 million in new contract wins.
Despite these exceptional fundamentals, the company's premium valuation reflects high market expectations and leaves limited room for disappointment.
While Pro Medicus remains a best-in-class business with strong long term prospects, the current risk-reward balance supports a view to trim holdings at current levels.
